News & Updates

Among South Asian adults, a culturally adapted, group-based lifestyle intervention does not appear to result in greater improvements in cardiovascular disease (CVD) risk factors as compared with written health education materials, according to the SAHELI study.

The SCOFF* trial presented at ESC 2024 shows that fasting is not necessary prior to cardiac catheterization procedures requiring conscious sedation.

Treatment with evogliptin falls short of providing protective benefits against calcification of the aortic valve (AV), but longer treatment may be helpful, reports a study.

GMRx2, a novel low-dose single pill containing three antihypertensive drugs – telmisartan, amlodipine, and indapamide – achieves all efficacy endpoints in two pivotal phase III trials presented at ESC 2024.

In patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), treatment with vutrisiran appears to reduce the risk of death from any cause and cardiovascular events while preserving functional capacity and quality of life, as shown in a study.

In the phase III HELIOS-B trial, vutrisiran reduced death and cardiovascular (CV) events in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

For atrial fibrillation (AF) patients with normal or impaired renal function, use of nonvitamin K antagonist oral anticoagulants (NOACs) results in improved outcomes relative to vitamin K antagonist (VKA) therapy, suggests a study presented at ESC 2024.